MTAP and mesothelioma: One of these drugs is L-alanosina, which has been evaluated in a phase 2 trial including 65 patients with MTAP-deficient solid tumors (16 mesotheliomas): there were no objective responses, although 24% had stable disease, including 2 patients with mesothelioma [31].